Pfizer-BioNTech COVID-19 vaccine-associated tinnitus and treatment with transcranial magnetic stimulation
QJM
.
2022 Sep 22;115(9):623-624.
doi: 10.1093/qjmed/hcac124.
Authors
Jiann-Jy Chen
1
2
,
Bing-Yan Zeng
3
,
Chun-Chung Lui
4
,
Tien-Yu Chen
5
6
,
Yen-Wen Chen
1
,
Ping-Tao Tseng
1
7
8
Affiliations
1
Prospect Clinic for Otorhinolaryngology & Neurology, Kaohsiung City, 81166, Taiwan.
2
Department of Otorhinolaryngology, E-Da Cancer Hospital, Kaohsiung, 82445, Taiwan.
3
Department of Internal Medicine, E-DA Dachang Hospital, Kaohsiung, 807, Taiwan.
4
Division of Medical Image, E-Da Cancer Hospital, Kaohsiung, 82445, Taiwan.
5
Department of Psychiatry, Tri-Service General Hospital; School of Medicine, National Defense Medical Center, Taipei, 114, Taiwan.
6
Institute of Brain Science, National Yang Ming Chiao Tung University, Taipei, 112, Taiwan.
7
Department of Psychology, College of Medical and Health Science, Asia University, Taichung, 413, Taiwan.
8
Institute of Biomedical Sciences, National Sun Yat-sen University, Kaohsiung, 804, Taiwan.
PMID:
35583323
PMCID:
PMC9129164
DOI:
10.1093/qjmed/hcac124
No abstract available
MeSH terms
BNT162 Vaccine* / adverse effects
COVID-19* / prevention & control
Humans
Tinnitus* / etiology
Tinnitus* / therapy
Transcranial Magnetic Stimulation / adverse effects
Substances
BNT162 Vaccine